Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | AADAC | P22760 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381761 | 1.00 | AR (0.42) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL29379156 | 0.85 | AR (0.43) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL24241054 | 0.85 | AR (0.43) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL29028876 | 0.85 | CYP3A4 (0.41) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL30512450 | 0.82 | AR (0.41) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL25380172 | 0.82 | AR (0.41) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL24241153 | 0.81 | NOTUM (0.45) | MAPK1ALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL30397234 | 0.81 | NOTUM (0.45) | MAPK1ALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL8975900 | 0.81 | ALDH1A1 (0.49) | ARCYP3A4SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL31214243 | 0.80 | CFTR (0.41) | SMN1; SMN2ALDH1A1LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340568-A1 | SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250320226-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | VERTEX PHARMA (US) | 2025-10-16 | — | — | US | disclosed |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4192829-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-04-17 | — | — | US | disclosed |
| US-12269831-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4525986-A1 | SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION | Vertex Pharmaceuticals Incorporated (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023150236-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4192829-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116171154-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2023-03-30 | — | — | US | disclosed |
| WO-2022109573-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022032068-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-02-10 | — | — | US | disclosed |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269831-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | AR 4693/4885CYP3A4 4406/4885SMN1; SMN2 4797/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AR 4692/4885CYP3A4 4125/4885SMN1; SMN2 4787/4885 |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | AR 3978/4885CYP3A4 4106/4885SMN1; SMN2 3077/4885 |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AR 4693/4885CYP3A4 4406/4885SMN1; SMN2 4797/4885 |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AR 4693/4885CYP3A4 4406/4885SMN1; SMN2 4797/4885 |
| US-20250340568-A1 | SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION | CFTR, SLC26A4, PKD1 | AR 3482/4885CYP3A4 515/4885SMN1; SMN2 3749/4885 |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AR 4693/4885CYP3A4 4406/4885SMN1; SMN2 4797/4885 |
| US-20250320226-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | CFTR, PKD1, AQP1 | AR 2056/4885CYP3A4 279/4885SMN1; SMN2 3160/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | AR 4693/4885CYP3A4 4406/4885SMN1; SMN2 4797/4885 |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AR 4693/4885CYP3A4 4406/4885SMN1; SMN2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.